Get the Stockscreener App
9.88
1.69%
-0.17
Pre-market:
9.88
Transcode Therapeutics Inc stock is traded at $9.88, with a volume of 15,230.
It is down -1.69% in the last 24 hours and up +24.28% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$10.05
Open:
$9.94
24h Volume:
15,230
Relative Volume:
0.07
Market Cap:
$9.06M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0371
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-0.90%
1M Performance:
+24.28%
6M Performance:
-14.12%
1Y Performance:
-96.73%
1-Day Range:
$9.3001
$10.05
1-Week Range:
$7.9914
$11.08
52-Week Range:
$6.0829
$316.28
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
9.88 | 9.22M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
What’s the beta of TransCode Therapeutics Inc. stockJuly 2025 Sentiment & Daily Stock Trend Watchlist - mfd.ru
Big Money Moves: Whats the beta of TransCode Therapeutics Inc stockWeekly Stock Recap & Trade Opportunity Analysis - baoquankhu1.vn
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial - TechStock²
Therapeutics, Inc. (RNAZ) Stock: Jumps as Company Expands RNA Cancer Program into Colorectal Indication - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Unveils Promising Glioblastoma Data with TTX-MC138 - timothysykes.com
TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade
TransCode Therapeutics: Promising Data Boosts Future Outlook - timothysykes.com
TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial - TipRanks
TransCode Therapeutics Announces IND Amendment for Phase 2a Trial - TradingView
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial With TTX-MC138 - 富途牛牛
Gainers Report: Does TransCode Therapeutics Inc have pricing powerRisk Management & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Gainers: Why is TransCode Therapeutics Inc stock going downCPI Data & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Risk Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Spike Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Intraday: What’s the beta of TransCode Therapeutics Inc. stock2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
What are analysts’ price targets for TransCode Therapeutics Inc.July 2025 Patterns & Entry Point Strategy Guides - mfd.ru
Earnings Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Market Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - baoquankhu1.vn
Short Squeeze: Should I hold or sell TransCode Therapeutics Inc nowJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Market Catalysts: Is TransCode Therapeutics Inc a speculative investmentQuarterly Portfolio Report & Fast Gain Swing Alerts - baoquankhu1.vn
Entry Recap: How does OLPX compare to its peersWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock in correction or buying zone2025 Volume Leaders & High Yield Equity Trading Tips - bollywoodhelpline.com
Options Flow: Does TransCode Therapeutics Inc have pricing powerJuly 2025 Earnings & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Fundamentals Check: Is TransCode Therapeutics Inc attractive for institutional investors2025 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn
Bull Bear: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Pullbacks & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Recap: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Will TransCode Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Gainers & AI Powered Market Entry Strategies - Улправда
MSN Money - MSN
Is TransCode Therapeutics Inc. stock attractive for income investorsBreathability and Upper Notes & HOKA model picks for your routine - ulpravda.ru
Will TransCode Therapeutics Inc. stock split again soonJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
Why retail investors pile into TransCode Therapeutics Inc. stockWeekly Trade Review & Reliable Entry Point Alerts - Улправда
TransCode Therapeutics, Inc.Common Stock (NQ: RNAZ - FinancialContent
Can TransCode Therapeutics Inc. stock double in next 5 years2025 Volatility Report & Risk Managed Trade Strategies - Улправда
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com Nigeria
(RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
How TransCode Therapeutics Inc. stock benefits from tech adoption2026 world cup usa national team quarterfinals midfield engines counter attacking knockout prediction tactical review - ulpravda.ru
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
TransCode’s glioblastoma therapy shows promise in preclinical study - Investing.com
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
TransCode reports positive phase 1 trial progress for cancer therapy - MSN
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics appoints Jack E. Stover to board of directors By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Industry Veteran Jack E. Stover to Board of Directors - citybuzz -
TransCode Therapeutics Strengthens Board with Veteran Financial Expert - TipRanks
Transcode Therapeutics Appoints Jack Stover to Board of Directors - TradingView — Track All Markets
TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com India
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):